Listing of Claims

The following listing of claims replaces all prior versions and listings of claims in the application.

1. (Original): Use of a dopamine receptor agonist or a pharmaceutically acceptable salt thereof for producing a topical pharmaceutical preparation for the local treatment of cutaneous tumours and warts.

2. (Currently amended): Use according to Claim 1, ~~characterised in that~~ wherein the dopamine receptor agonist is a dopamine D_2 receptor agonist.

3. (Currently amended): Use according to Claim 1 [[or 2]], ~~characterised in that~~ wherein the dopamine receptor agonist is bromocriptine, pergolide, selegiline, ropirinole, pramipexole or cabergolide.

4. (Currently amended): Use according to ~~one of Claims 1 to 3, characterised in that in~~ Claim 1, wherein in the case of the cutaneous tumours it is a question of cutaneous tumours of the preliminary stage of cancer or non-metastasising carcinomas of the skin.

5. (Currently amended): Use according to ~~one of Claims 1 to 4, characterised in that in~~ Claim 1, wherein in the case of the cutaneous tumours it is a question of actinic keratoses, basalioma or bowenoids.

6. (Currently amended): Use according to ~~one of Claims 1 to 3, characterised in that in~~ Claim 1, wherein in the case of the warts it is a question of interdigital warts, plane warts, plantar warts, vulgar warts or condyloma.

7. (Currently amended): Use according to ~~one of Claims 1 to 6, characterised in that~~ Claim 1, wherein the pharmaceutical preparation contains a dopamine receptor agonist or a pharmaceutically acceptable salt thereof in a quantity from 0.1 wt.% to 10 wt.%, relative to the pharmaceutical preparation.

8. (Currently amended): Use according to Claim 7, ~~characterised in that~~ wherein the pharmaceutical preparation contains a dopamine receptor agonist or a pharmaceutically acceptable salt thereof in a quantity from 0.25 wt.% to 0.5 wt.%, relative to the pharmaceutical preparation.

9. (Currently amended): Use according to Claim 8, ~~characterised in that~~ wherein the pharmaceutical preparation contains bromocriptine or a pharmaceutically acceptable salt thereof in a quantity from 0.25 wt.% to 0.5 wt.%, relative to the pharmaceutical preparation.

10. (Currently amended): Use according to ~~one of Claims 1 to 9, characterised in that~~ Claim 1, wherein the pharmaceutical preparation is present in the form of an ointment, a paste, a lotion, a creme or a gel.

11. (Currently amended): Use according to ~~one of Claims 1 to 10, characterised in~~ Claim 1, wherein that the pharmaceutical preparation contains conventional adjuvants, excipients and/or diluents.

12. (Currently amended): Use according to ~~one of the preceding claims, characterised in that~~ Claim 1, wherein the pharmaceutical preparation is applied locally onto the affected cutaneous areas once or several times a day.

13. (Currently amended): Use according to ~~one of the preceding claims, characterised in that~~ Claim 1, wherein the use of the pharmaceutical preparation is undertaken together with a medicinal treatment that is matched to the disease.

14. (Currently amended): Use according to ~~one of the preceding claims, characterised in that~~ Claim 1, wherein the use of the topical pharmaceutical preparation is undertaken together with an oral adjuvant therapy involving a dopamine receptor agonist.

15. (Currently amended): Use according to ~~one of the preceding claims, characterised in that~~ Claim 1, wherein the pharmaceutical preparation contains dimethyl sulfoxide.

16. (Currently amended): Use according to Claim 15, ~~characterised in that~~ wherein the pharmaceutical preparation contains 5-20 wt.% dimethyl sulfoxide, preferably 10-15 wt.%, relative to the pharmaceutical preparation.